HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: CJN.00360107v1 2/5/947    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Azizi, M. Articles by Bura-Rivière, A. Search for Related Content PubMed PubMed Citation Articles by Azizi, M. Articles by Bura-Rivière, A.

Hormonal and Hemodynamic Effects of Aliskiren and Valsartan and Their Combination in Sodium-Replete Normotensive Individuals

Michel Azizi^*,,, Joël Ménard^*,,, Alvine Bissery, Than-Tam Guyene, and Alessandra Bura-Rivière^,

^* Université Paris Descartes, Faculté de Médecine, Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, and INSERM, CIC 9201, Paris, France

Address correspondence to: Dr. Michel Azizi, Centre d'Investigations Cliniques, Hôpital Européen Georges Pompidou, 20–40 rue Leblanc, 75908 Paris cedex 15, France. Phone: +33-1-5609-2911; Fax: +33-1-5609-2929; E-mail: michel.azizi{at}egp.ap-hop-paris.fr

Background and Objectives: An AT₁ receptor antagonist induces a counterregulatory renin release whose intensity and duration reflect the magnitude of the renin-angiotensin blockade. We investigated whether a renin inhibitor may neutralize this counterregulation and amplify the effects of AT₁ receptor antagonists.

Design, Setting, Participants, & Measurements: In 12 normotensive male individuals who were on a high-sodium diet, a double-blind, placebo-controlled, randomized, crossover design was used to study the hormonal and BP effects of single oral administrations of 300 mg of the renin inhibitor aliskiren, 320 mg of valsartan, and a combination of these two drugs, each at half dosage (150 mg of aliskiren and 160 mg of valsartan).

Results: Valsartan (320 mg) increased plasma renin activity and angiotensin I and angiotensin II levels, but 300 mg of aliskiren decreased them for 48 h. Aliskiren (300 mg) stimulated immunoreactive renin release more strongly than 320 mg of valsartan, decreased urinary aldosterone excretion for longer than 320 mg of valsartan, and had a similar BP-lowering effect as 320 mg of valsartan. In combination, 150 mg of aliskiren neutralized the valsartan (160 mg)-induced increase in plasma angiotensins for 48 h. The renin and aldosterone effects of the combination of 150 mg of aliskiren and 160 mg of valsartan were similar to those of 300 mg of aliskiren and greater than those of 320 mg of valsartan. When plasma drug concentrations were taken into account, the combination of 150 mg of aliskiren and 160 mg of valsartan had a synergistic effect on renin release. The BP-lowering effect of 150 mg of aliskiren and 160 mg of valsartan was similar to that of 300 mg of aliskiren and 320 mg of valsartan at peak but was more prolonged.

Conclusion: The stronger and longer lasting effects on plasma active renin and urinary aldosterone of aliskiren, alone or in combination, demonstrate a more effective blockade of the renin-angiotensin system than that obtained with 320 mg of valsartan alone.

This article has been cited by other articles:

				D. J. Campbell Response to the Renin Rise With Aliskiren: It's Simply Stoichiometry Hypertension, April 1, 2008; 51(4): e29 - e29. [Full Text] [PDF]

				D. J. Campbell Interpretation of Plasma Renin Concentration in Patients Receiving Aliskiren Therapy Hypertension, January 1, 2008; 51(1): 15 - 18. [Full Text] [PDF]